Long-term single antiplatelet therapy for patients with acute coronary syndrome at high-risk for ischemia and bleeding: a precision cohort study - Report - MDSpire
Advertisement
Long-term single antiplatelet therapy for patients with acute coronary syndrome at high-risk for ischemia and bleeding: a precision cohort study
Clinical Report: Long-term Outcomes of SAPT in High-Risk ACS Patients
Overview
This study evaluates the outcomes of single antiplatelet therapy (SAPT) with aspirin versus clopidogrel in high-risk acute coronary syndrome (ACS) patients post-percutaneous coronary intervention (PCI). Clopidogrel was associated with lower rates of major adverse cardiovascular and cerebrovascular events (MACCE) and target vessel revascularization (TVR) compared to aspirin, without increasing bleeding risks.
Background
Acute coronary syndrome (ACS) encompasses serious cardiovascular conditions that require effective antiplatelet therapy to prevent thrombotic events. Current guidelines recommend transitioning patients from dual antiplatelet therapy (DAPT) to SAPT after 12 months, but the optimal choice between aspirin and clopidogrel remains uncertain, particularly for high-risk patients. Understanding the comparative effectiveness of these therapies is crucial for improving patient outcomes.
Data Highlights
Outcome
Aspirin (n=435)
Clopidogrel (n=207)
P-value
NACE
Similar
Similar
-
MACCE
9.2%
4.3%
0.031
TVR
6.4%
1.4%
0.006
Key Findings
The incidence of NACE was similar between aspirin and clopidogrel cohorts.
Clopidogrel significantly reduced MACCE compared to aspirin (4.3% vs. 9.2%, P = 0.031).
Clopidogrel also showed a lower rate of TVR compared to aspirin (1.4% vs. 6.4%, P = 0.006).
Cox regression analysis indicated that MACCE and TVR rates were significantly lower in the clopidogrel cohort.
No significant increase in bleeding complications was observed with clopidogrel compared to aspirin.
Clinical Implications
Clinicians should consider clopidogrel as a preferred option for long-term SAPT in high-risk ACS patients transitioning from DAPT, as it is associated with better cardiovascular outcomes without increasing bleeding risks. This finding supports a more individualized approach to antiplatelet therapy in this patient population.
Conclusion
The study highlights the potential benefits of clopidogrel over aspirin for long-term SAPT in high-risk ACS patients, emphasizing the need for personalized treatment strategies to optimize patient outcomes.
The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.
Most U.S. adults with hypertension missed blood pressure targets—including those on treatment—highlighting gaps in initiation and intensification of therapy, new JAMA data show.
